References

Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin a

10.1073/pnas.89.9.3686 · 1992 · External reference

Calcineurin inhibitor nephrotoxicity

10.2215/cjn.04800908 · 2009 · External reference

The many faces of calcineurin inhibitor toxicity-what the FK?

10.1053/j.ackd.2019.08.006 · 2020 · External reference

A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation

10.1056/nejm199410273311702 · 1994 · External reference

Pregnancy outcomes after liver transplantation: a systematic review and meta-analysis

10.14309/ajg.0000000000001105 · 2021 · External reference

Fetal toxicity of immunosuppressive drugs in pregnancy

10.3390/jcm7120552 · 2018 · External reference

Safety of tacrolimus in pregnancy

2014 · External reference

Pregnancy following liver transplantation: review of outcomes and recommendations for management

10.1155/2012/137129 · 2012 · External reference

Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus

10.1097/00007890-200012270-00010 · 2000 · External reference

Pregnancy outcomes in kidney transplant recipients: a systematic review and meta-analysis

10.1111/j.1600-6143.2011.03656.x · 2011 · External reference

Pregnancy outcomes in women with kidney transplant: meta-analysis and systematic review

10.1186/s12882-019-1213-5 · 2019 · External reference

European best practice guidelines for renal transplantation sec IV 10: pregnancy in renal transplant recipients

10.1093/ndt/17.suppl_4.50 · 2002 · External reference

Clinical practice guideline on pregnancy and renal disease

10.1186/s12882-019-1560-2 · 2019 · External reference

2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases

10.1002/art.41191 · 2020 · External reference

Maternal hemodynamics and pregnancy outcome in women with prior orthotopic liver transplantation

10.1002/lt.500060223 · 2000 · External reference

Cyclosporine use during pregnancy

10.1007/s40264-013-0034-x · 2013 · External reference

Longterm neurodevelopment of children exposed in utero to cyclosporine after maternal renal transplant

10.2165/11316280-000000000-00000 · 2010 · External reference

In utero exposure to immunosuppressive drugs: experimental and clinical studies

10.1007/s00467-001-0776-z · 2002 · External reference

Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion lading to glucose dysregulation and diabetes mellitus

10.1002/cpt.546 · 2017 · External reference

Pregnancy outcomes in female patients exposed to cyclosporin-based versus tacrolimus-based immunosuppressive regimens after liver/kidney transplantation: a systematic review and meta-analysis

10.1111/jcpt.13340 · 2021 · External reference

Pregnancy and neonatal outcomes in women receiving calcineurin inhibitors: a systematic review and meta-analysis

10.1111/bcp.15414 · 2022 · External reference

Kidney adverse events associated with calcineurin inhibitors: a real-world study based on the FAERS database and network pharmacology

10.3389/fmed.2026.1764130 · 2026 · External reference

Calcineurin inhibitors and risk of CNS infections: a disproportionality analysis of the FDA adverse event reporting system (FAERS)

10.1016/j.clinthera.2025.05.004 · 2025 · External reference

Thrombotic microangiopathy associated with calcineurin inhibitors: a real-world analysis of postmarketing surveillance data

10.1016/j.clinthera.2024.11.017 · 2025 · External reference

A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil

10.1111/andr.13533 · 2024 · External reference

Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: a disproportionality analysis using the Food and Drug Administration adverse event reporting system

10.3389/fphar.2022.1063625 · 2022 · External reference

A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database

10.3389/fphar.2024.1442002 · 2024 · External reference

A disproportionality analysis of insulin glargine in the overall population and in pregnant women using the FDA adverse event reporting system (FAERS) database

10.1371/journal.pone.0331489 · 2024 · External reference

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety

10.1002/prp2.1161 · 2024 · External reference

Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study

10.3389/fphar.2024.1399172 · 2024 · External reference

Post-marketing safety concerns with rimegepant based on a pharmacovigilance study

10.1186/s10194-024-01858-4 · 2024 · External reference

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database

10.3389/fphar.2024.1338902 · 2024 · External reference

Overview of pregnancy in renal transplant patients

10.1155/2016/4539342 · 2016 · External reference

Pharmacologic considerations for solid organ transplant recipients who become pregnant

10.1002/phar.1800 · 2016 · External reference

Usage of tacrolimus and mycophenolic acid during conception, pregnancy, and lactation, and its implications for therapeutic drug monitoring: a systematic critical review

10.1097/ftd.0000000000000769 · 2020 · External reference

Pregnancy in Irish renal transplant recipients in the cyclosporine era

10.1007/bf03170477 · 2000 · External reference

Effect of pregnancy on long-term kidney function in renal transplant recipients treated with cyclosporine and with azathioprine

10.1111/j.1600-6143.2005.01091.x · 2005 · External reference

Preeclampsia after kidney transplantation: rates and association with graft survival and function

10.2215/cjn.0000000000000155 · 2023 · External reference

Double jeopardy: the complicated interplay of preeclampsia risks to mom, baby, and allograft in kidney transplant recipients

10.2215/cjn.0000000000000210 · 2023 · External reference

Immunosuppressant drug tacrolimus inhibits HUVEC angiogenesis and production of placental growth factor

10.1016/j.placenta.2024.12.010 · 2025 · External reference

Pregnancy after organ transplantation: a report from the UK transplant pregnancy registry

10.1097/01.tp.0000263357.44975.d0 · 2007 · External reference

Antiplatelet agents for preventing pre-eclampsia and its complications

10.1002/14651858.cd004659.pub2 · 2007 · External reference

Perinatal outcomes after liver transplantation: is there a role for aspirin treatment?

10.3390/jcm12113733 · 2023 · External reference

Prevalence of major malformations and small for gestational age in newborns of female transplant recipients on tacrolimus-containing regimens during pregnancy

10.1016/j.ajt.2025.07.2472 · 2025 · External reference

What is the teratogenic risk of mycophenolate?

10.1055/s-0036-1597933 · 2017 · External reference

Mycophenolate mofetil embryopathy: a newly recognized teratogenic syndrome

10.1016/j.ejmg.2016.09.014 · 2017 · External reference

Major congenital malformations after first-trimester exposure to ACE inhibitors

10.1056/nejmoa055202 · 2016 · External reference

Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: a systematic review and meta-analysis

10.1002/prp2.644 · 2020 · External reference

Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review

10.1161/hypertensionaha.112.196352 · 2012 · External reference

Hypertrophic cardiomyopathy secondary to tacrolimus therapy in a kidney transplant patient: a case report and focused review of the literature

10.1002/ccr3.6539 · 2022 · External reference

Tacrolimus-related hypertrophic cardiomyopathy in an adult cardiac transplant patient

2012 · External reference

Pathogenesis of calcineurin inhibitor-induced hypertension

10.5301/jn.5000174 · 2012 · External reference

Comparison of pregnancy outcomes in Dutch kidney recipients with and without calcineurin inhibitor exposure: a retrospective study

10.1111/tri.14156 · 2021 · External reference

Chronic calcineurin inhibitor nephrotoxicity-lest we forget

10.1111/j.1600-6143.2011.03504.x · 2011 · External reference

Nephrotoxicity of calcineurin inhibitors in kidney epithelial cells is independent of NFAT signaling

10.3389/fphar.2021.789080 · 2022 · External reference

Immunosuppression with cyclosporine versus tacrolimus shows distinctive nephrotoxicity profiles within renal compartments

10.1111/apha.14190 · 2024 · External reference

Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras

10.1097/tp.000000000000124 · 2016 · External reference

Cyclosporin a but not FK506 activates the integrated stress response in human cells

10.1074/jbc.ra120.014531 · 2020 · External reference

Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients

10.1002/14651858.cd003961.pub2 · 2005 · External reference

Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile

10.1111/j.1600-6143.2004.00427.x · 2004 · External reference

Recent topics on the mechanisms of immunosuppressive therapy-related neurotoxicities

10.3390/ijms20133210 · 2019 · External reference

A case of tacrolimus-induced reversible cerebral vasoconstriction syndrome after heart transplantation

10.1007/s11748-020-01309-2 · 2020 · External reference

Reversible cerebral vasoconstriction syndrome post-cardiac transplantation: a therapeutic dilemma: case report

10.1186/s12883-024-03780-3 · 2024 · External reference

Two rare neurologic complications after heart transplantation: posterior reversible encephalopathy syndrome, followed by reversible cerebral vasoconstriction syndrome

10.1016/j.healun.2016.01.1221 · 2016 · External reference

Tacrolimus-induced reversible crebral vasoconstriction syndrome with delayed multi-segmental vasoconstriction

10.1016/j.jstrokecerebrovasdis.2017.03.006 · 2017 · External reference

The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients

10.1093/brain/awm256 · 2007 · External reference

Perfusion-dependent focal neurologic deficits in a critically ill heart transplant recipient: a case of tacrolimus-associated reversible cerebral vasospasm syndrome?

10.1053/j.jvca.2023.03.044 · 2023 · External reference

Interpreting tacrolimus concentrations during pregnancy and postpartum

10.1097/tp.0b013e318278d367 · 2013 · External reference

Impaired function of cerebral parenchymal arterioles in experimental preeclampsia

10.1016/j.mvr.2018.04.007 · 2018 · External reference

Thrombotic microangiopathy in a pregnant woman with kidney transplantation: a case report

10.1016/j.jogc.2020.10.018 · 2021 · External reference

Cyclosporine-induced thrombotic microangiopathy in pregnant women: a case report and literature review

10.1177/2050313x241308693 · 2025 · External reference

Drug-induced thrombotic microangiopathy: a systematic review of published reports

10.1182/blood-2014-11-611335 · 2015 · External reference

Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient

10.1136/bcr-2012-007351 · 2013 · External reference

De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus

10.1007/s00467-014-3036-8 · 2015 · External reference

Thrombotic microangiopathy in pregnancy: current understanding and management strategies

10.1016/j.ekir.2024.05.016 · 2024 · External reference

Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management

10.3389/fphar.2022.1088031 · 2023 · External reference